May 12, 2020 / 06:20PM GMT
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research Analyst
Okay. Good afternoon, everyone. Welcome to the afternoon sessions of the first day of the BofA Virtual Vegas Conference. My name is Geoff Meacham, I'm the senior biopharma analyst at BofA here, and I have Alec Stranahan from my team as well. And we're thrilled to have Moderna present this afternoon.
And speaking on behalf of Moderna, we have Stéphane Bancel, who is CEO. We also have Lorence Kim who's CFO. Guys, are you there?
Lorence H. Kim - Moderna, Inc. - CFO & Treasurer
Yes.
Stéphane Bancel - Moderna, Inc. - CEO & Director
Thank you for having us.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research AnalystOkay. Perfect. Let's get right into it. So Stéphane, obviously, you've had a lot of success and a lot of visibility with respect to the COVID vaccine. I want to get a sense from you. What
Trustpilot
